Amwell reports Q3 revenue of $56.3 million and net loss of $31.9 million

Reuters
11/05
Amwell reports Q3 revenue of $56.3 million and net loss of $31.9 million

American Well Corporation reported third quarter 2025 subscription revenue of $30.9 million and Amwell Medical Group visit revenue of $21.2 million. The company achieved a gross margin of 52.4%. Net loss was $31.9 million, compared to a net loss of $19.5 million in the previous quarter. Adjusted EBITDA was negative $12.7 million, compared to negative $4.7 million in the second quarter. Total visits reached 1.1 million. For full-year 2025, Amwell updated its revenue guidance to a range of $245 million to $248 million and narrowed its Adjusted EBITDA guidance to negative $45 million to negative $42 million. The company expects Amwell Medical Group visits between 1.3 million and 1.35 million. For the fourth quarter, revenue is expected to be between $51 million and $54 million, with Adjusted EBITDA between negative $15 million and negative $12 million. Amwell reiterated its objective to achieve positive cash flow from operations in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Well Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-264710), on November 04, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10